2024
Brief Report: Should a prior cancer history be reevaluated as an exclusion for clinical trial participation?
Ayoade O, Canavan M, Caturegli G, Boffa D. Brief Report: Should a prior cancer history be reevaluated as an exclusion for clinical trial participation? Lung Cancer 2024, 198: 108032. PMID: 39561624, DOI: 10.1016/j.lungcan.2024.108032.Peer-Reviewed Original ResearchAmerican College of Surgeons Operative Standards and Breast Cancer Outcomes
Taylor C, Wang T, Baskin A, Sinco B, Hughes T, Boffa D, Boughey J, Dossett L. American College of Surgeons Operative Standards and Breast Cancer Outcomes. JAMA Network Open 2024, 7: e2446345. PMID: 39565622, PMCID: PMC11579798, DOI: 10.1001/jamanetworkopen.2024.46345.Peer-Reviewed Original ResearchMA08.12 Semi-Sold Lung Nodule Growth Rates, Need for Treatment, and Cancer-Specific Verses All-Cause Mortality in a Large North American Population
Woodard G, Kane E, Prince S, Blasberg J, Dhanasopon A, Boffa D, Mase V, Dacic S, Bader A, Detterbeck F. MA08.12 Semi-Sold Lung Nodule Growth Rates, Need for Treatment, and Cancer-Specific Verses All-Cause Mortality in a Large North American Population. Journal Of Thoracic Oncology 2024, 19: s87. DOI: 10.1016/j.jtho.2024.09.156.Peer-Reviewed Original ResearchLung Cancer Screening at US Hospitals for People Lacking Primary Care
DeSantis W, Ayoade O, Caturegli G, Boffa D. Lung Cancer Screening at US Hospitals for People Lacking Primary Care. JAMA Network Open 2024, 7: e2442373. PMID: 39480427, PMCID: PMC11528307, DOI: 10.1001/jamanetworkopen.2024.42373.Peer-Reviewed Original ResearchEP.07C.10 Real-World Outcomes of Patients Treated with Neoadjuvant Immunotherapy for Resectable Non-Small Cell Lung Cancer
Ermer T, Kim S, Goldberg S, Zolfaghari E, Blasberg J, Boffa D, Herbst R, Politi K, Schalper K, Dacic S, Woodard G. EP.07C.10 Real-World Outcomes of Patients Treated with Neoadjuvant Immunotherapy for Resectable Non-Small Cell Lung Cancer. Journal Of Thoracic Oncology 2024, 19: s543-s544. DOI: 10.1016/j.jtho.2024.09.1007.Peer-Reviewed Original ResearchTreatment patterns and clinical outcomes in patients with EGFR-mutated non-small cell lung cancer after progression on osimertinib
Robinson N, Canavan M, Zhan P, Udelsman B, Pathak R, Boffa D, Goldberg S. Treatment patterns and clinical outcomes in patients with EGFR-mutated non-small cell lung cancer after progression on osimertinib. Clinical Lung Cancer 2024 PMID: 39462746, DOI: 10.1016/j.cllc.2024.09.006.Peer-Reviewed Original ResearchNon-small cell lung cancerEGFR-mutant non-small cell lung cancerFirst-line osimertinibContinuation of osimertinibImmune checkpoint inhibitorsTyrosine kinase inhibitorsCell lung cancerRetrospective cohort studyOverall survivalTreatment regimensLung cancerAdvanced epidermal growth factor receptorAssociated with increased PFSAssociated with superior PFSSecond-line treatment regimenEGFR exon 19 deletionRetrospective cohort study of patientsEGFR tyrosine kinase inhibitorsAssociated with prolonged survivalCohort study of patientsSecond-line treatment regimensExon 19 deletionFirst-line therapyEpidermal growth factor receptorFirst-line treatmentFurther insights into MARS 2
Zhan P, Boffa D, Woodard G. Further insights into MARS 2. The Lancet Respiratory Medicine 2024, 12: e52. PMID: 39214641, DOI: 10.1016/s2213-2600(24)00251-0.Peer-Reviewed Original ResearchSurgical and Endoscopic Management of Clinical T1b Esophageal Cancer
Ayoade O, Canavan M, De Santis W, Zhan P, Boffa D. Surgical and Endoscopic Management of Clinical T1b Esophageal Cancer. Journal Of Thoracic And Cardiovascular Surgery 2024 PMID: 38925509, DOI: 10.1016/j.jtcvs.2024.06.011.Peer-Reviewed Original ResearchEsophageal cancerTumor attributesEsophagectomy patientsEndoscopic treatmentAccelerated time failure modelsEndoscopic managementTumor size > 1 cmFactors associated with upstagingOccult lymph node metastasisAssociated with improved survivalAssociated with lymphovascular invasionEffect of esophagectomyT1b esophageal cancerTreatment naive patientsNational Cancer DatabaseWell-differentiated tumorsKaplan Meier analysisLymph node metastasisPoor tumor differentiationTime failure modelsNodal upstagingLymphovascular invasionOverall survivalEndoscopic patientsMeier analysisASO Visual Abstract: National Cancer Database Conforms with Standardized Framework for Registry and Data Quality
Palis B, Janczewski L, Browner A, Cotler J, Nogueira L, Richardson L, Benard V, Wilson R, Walker N, McCabe R, Boffa D, Nelson H. ASO Visual Abstract: National Cancer Database Conforms with Standardized Framework for Registry and Data Quality. Annals Of Surgical Oncology 2024, 31: 5589-5590. DOI: 10.1245/s10434-024-15584-3.Peer-Reviewed Original ResearchThe National Cancer Database Conforms to the Standardized Framework for Registry and Data Quality
Palis B, Janczewski L, Browner A, Cotler J, Nogueira L, Richardson L, Benard V, Wilson R, Walker N, McCabe R, Boffa D, Nelson H. The National Cancer Database Conforms to the Standardized Framework for Registry and Data Quality. Annals Of Surgical Oncology 2024, 31: 5546-5559. PMID: 38717542, PMCID: PMC11300494, DOI: 10.1245/s10434-024-15393-8.Peer-Reviewed Original ResearchNational Program of Cancer RegistriesCenters for Disease Control and PreventionCancer RegistryNational Cancer InstituteU.S. Cancer StatisticsDisease Control and PreventionControl and PreventionRate of complianceNational Cancer DatabaseRe-abstractedHospital complianceRegistries' abilityStaff credentialingCancer statisticsHospital benchmarkingAssessed timelinessCancer surveillanceCancer casesData submissionInternal consistencyCase identificationEvaluate adherenceRegistryPolicy decision-makingCancer InstituteAssociation of patient socioeconomic status with outcomes after palliative treatment for disseminated cancer
Maduka R, Canavan M, Walters S, Ermer T, Zhan P, Kaminski M, Li A, Pichert M, Salazar M, Prsic E, Boffa D. Association of patient socioeconomic status with outcomes after palliative treatment for disseminated cancer. Cancer Medicine 2024, 13: e7028. PMID: 38711364, PMCID: PMC11074703, DOI: 10.1002/cam4.7028.Peer-Reviewed Original ResearchConceptsOptimal quality of careQuality of carePatient socioeconomic statusAssociated with improved qualityAssociated with improved quality of lifeEnd-of-lifeUS cancer populationPalliative treatmentQuality of lifeCox proportional hazards modelsMultivariate logistic regressionInformed decision makingProportional hazards modelFacility characteristicsNon-HispanicAssociated with lower ratesInsurance payer statusImproving informed decision makingCancer populationSocioeconomic statusHispanic ethnicityTreatment usePayer statusBlack raceLogistic regressionSalvage lung resection after immunotherapy is feasible and safe
Nemeth A, Canavan M, Zhan P, Udelsman B, Ely S, Wigle D, Martin L, Yang C, Boffa D, Dhanasopon A. Salvage lung resection after immunotherapy is feasible and safe. JTCVS Open 2024, 20: 141-150. PMID: 39296459, PMCID: PMC11405986, DOI: 10.1016/j.xjon.2024.03.018.Peer-Reviewed Original ResearchNon-small cell lung cancerComplete pathologic responseSalvage lung resectionNational Cancer DatabaseLength of stayStages I-IVLung resectionOligo-progressionOverall survivalSalvage surgeryComplete resection (R0Comprehensive multidisciplinary treatment planHigher R0 resection rateCohort study of patientsInitiation of immunotherapyR0 resection rateTreated with immunotherapySalvage treatment optionMortality rateCell lung cancerLow patient morbidityMedian length of stayKaplan-Meier analysisMultidisciplinary treatment planStudy of patientsIdentifying Opportunities to Deliver High‐Quality Cancer Care Across a Health System: A Clinical Responsibility
Shah H, Cohen O, Bourdillon A, Burtness B, Boffa D, Young M, Judson B, Mehra S. Identifying Opportunities to Deliver High‐Quality Cancer Care Across a Health System: A Clinical Responsibility. Otolaryngology 2024, 171: 445-456. PMID: 38606669, DOI: 10.1002/ohn.755.Peer-Reviewed Original ResearchOral squamous cell carcinomaHealth systemCancer careLymph node yieldDeliver high-quality cancer careHigh-quality cancer careBaseline quality of careReporting of Observational StudiesFragmentation of careQuality of careFacility typeCommunity facilitiesOdds of positive surgical marginsAssociated with increased oddsPositive surgical margin rateCombination groupAcademic centersPositive surgical marginsTreating facility typeSurgical margin ratePrimary outcome measureSquamous cell carcinomaGuideline-adherent treatmentCombined careEpidemiology guidelinesRenovating the Commission on Cancer’s Quality Measure Portfolio
Boffa D, Lum S, Palis B, McCabe R, Park K, Siddiqui M, Facktor M, Mullet T, Nelson H. Renovating the Commission on Cancer’s Quality Measure Portfolio. Annals Of Surgery 2024, 280: 193-198. PMID: 38545786, DOI: 10.1097/sla.0000000000006281.Peer-Reviewed Original ResearchSurvival Among Patients With High-Risk Gastrointestinal Cancers During the COVID-19 Pandemic
Janczewski L, Browner A, Cotler J, Palis B, Chan K, Joung R, Bentrem D, Merkow R, Boffa D, Nelson H. Survival Among Patients With High-Risk Gastrointestinal Cancers During the COVID-19 Pandemic. JAMA Network Open 2024, 7: e240160. PMID: 38441896, PMCID: PMC10915687, DOI: 10.1001/jamanetworkopen.2024.0160.Peer-Reviewed Original ResearchConceptsStage IV diseaseRetrospective cohort studyCohort studyQuality care deliveryIV diseaseOperative mortalityHigh riskPandemic-related stressorsAssociated with increased 1-year mortalityDiagnosis of stage IMultivariate logistic regressionCOVID-19 pandemicCare deliveryNational Cancer DatabaseKaplan-Meier curvesEvaluate 30-dayMain OutcomesFollow-up dataCancer communityPrepandemic levelsLogistic regressionCancer DatabaseCOVID-19COVID-19 infectionMalignant neoplasmsMedicaid Expansion Under the Affordable Care Act and Early Mortality Following Lung Cancer Surgery
Nogueira L, Boffa D, Jemal A, Han X, Yabroff K. Medicaid Expansion Under the Affordable Care Act and Early Mortality Following Lung Cancer Surgery. JAMA Network Open 2024, 7: e2351529. PMID: 38214932, PMCID: PMC10787311, DOI: 10.1001/jamanetworkopen.2023.51529.Peer-Reviewed Original ResearchConceptsMedicaid expansion statusNon-small cell lung cancerMedicaid expansion statesMedicaid expansionSurgical resection of non-small cell lung cancerResection of non-small cell lung cancerDifference-in-differencesExpansion statesPatients' state of residenceNonexpansion statesCohort studyAssociation of Medicaid expansionExpansion statusPostoperative mortalityDifference-in-differences analysisStudy population characteristicsState of residenceAffordable Care ActHealth insurance coverageCohort study of patientsSurgical resectionEarly mortalityMain OutcomesAssociated with declinesCancer outcomes
2023
So Now We Know—Reflections on the Extent of Resection for Stage I Lung Cancer
Detterbeck F, Ely S, Udelsman B, Blasberg J, Boffa D, Dhanasopon A, Mase V, Woodard G. So Now We Know—Reflections on the Extent of Resection for Stage I Lung Cancer. Clinical Lung Cancer 2023, 25: e113-e123. PMID: 38310034, DOI: 10.1016/j.cllc.2023.12.007.Peer-Reviewed Original ResearchStage I lung cancerI lung cancerSublobar resectionRecurrence-free survivalHealthy patientsLung cancerRecent trialsInadequate resection marginsLarge recent trialsAdditional randomized trialsHigh-level evidenceOverall survival differenceExtent of resectionLong-term outcomesLong-term resultsHigh locoregional recurrenceAspects of patientsLesser resectionsLocoregional recurrencePerioperative morbidityIntraoperative detailsLung functionResection extentResection marginsPostoperative changesNational Cancer Database Reports Ongoing Disruptions in Cancer Diagnoses in 2021
Janczewski L, Browner A, Cotler J, Palis B, McCabe R, Boffa D, Nelson H. National Cancer Database Reports Ongoing Disruptions in Cancer Diagnoses in 2021. Annals Of Surgical Oncology 2023, 31: 729-730. PMID: 38062292, DOI: 10.1245/s10434-023-14748-x.Peer-Reviewed Original ResearchTelehealth Availability for Cancer Care During the COVID-19 Pandemic: Cross-Sectional Study
Marks V, Hsiang W, Nie J, Umer W, Haleem A, Galal B, Pak I, Kim D, Salazar M, Pantel H, Berger E, Boffa D, Cavallo J, Leapman M. Telehealth Availability for Cancer Care During the COVID-19 Pandemic: Cross-Sectional Study. JMIR Cancer 2023, 9: e45518. PMID: 37917149, PMCID: PMC10654905, DOI: 10.2196/45518.Peer-Reviewed Original ResearchCancer HospitalCancer careTelehealth availabilityTotal admissionsTelehealth servicesCancer typesBreast cancer careComprehensive cancer programsCross-sectional studySkin cancer careFacility-level factorsNational Cancer InstituteCOVID-19 pandemicTelehealth visitsAccountable care organizationsCommon cancerCancer programsOutpatient careCancer sitesNew patientsCancer InstitutePatientsSkin cancerHospitalMost hospitalsImpact of the COVID-19 Pandemic on Lung Cancer Screening Processes in a Northeast Tertiary Health Care Network
Udelsman B, Detterbeck F, Tanoue L, Mase V, Boffa D, Blasberg J, Dhanasopon A, Ely S, Mazzarelli L, Bader A, Woodard G. Impact of the COVID-19 Pandemic on Lung Cancer Screening Processes in a Northeast Tertiary Health Care Network. Journal Of Computer Assisted Tomography 2023, 48: 222-225. PMID: 37832536, DOI: 10.1097/rct.0000000000001549.Peer-Reviewed Original ResearchHealth care networkLung cancer screening processLung cancer screening programsCare networkCancer screening programsCoronavirus disease 2019 (COVID-19) pandemicComputed tomography scanCOVID-19 hospitalizationCOVID-19 surgeCancer screening processDisease 2019 pandemicLung cancer diagnosisHealth care systemAverage hospitalizationRadiology databaseLung cancerTomography scanScreening programCare systemCancer diagnosisMonthsHospitalizationCOVID-19COVID-19 pandemicPandemic